Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2011-06-14
2011-06-14
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C564S099000, C514S595000, C514S605000
Reexamination Certificate
active
07960584
ABSTRACT:
This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.
REFERENCES:
patent: 2003/0153596 (2003-08-01), Suh et al.
patent: 2004/0157865 (2004-08-01), Codd et al.
patent: WO 02/16318 (2002-02-01), None
patent: WO 03/049702 (2003-06-01), None
patent: WO 03/095420 (2003-11-01), None
patent: WO 2005/003084 (2005-01-01), None
Gunthorpe et al. Current Pharmaceutical Design 2008, 14, 32-41.
Schafer et al. Drug Discovery Today 2008, 13 (21/22), 913-916.
Horig et al. Journal of Translational Medicine 2004, 2(44).
Mezey, E. et al., “Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human”, PNAS, vol. 97, No. 7, pp. 3655-3660, Mar. 28, 2000.
Cortright, D. et al., “The Tissue Distribution and Functional Characterization of Human VR1”,Biochemical and Biophysical Research Communications, vol. 281, pp. 1183-1189, Feb. 6, 2001.
Nagy, I. et al., “The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology”,European Journal of Pharmacology, vol. 500, pp. 351-369, Aug. 17, 2004.
Petersen, K. et al., “Capsaicin evoked pain and allodynia in post-herpetic neurlalgia”,PAIN, vol. 88, pp. 125-133, Apr. 11, 2000.
Walker, K. et al., “The VR1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic Pain”,The Journal of Pharmacology and Experimental Therapeutics, vol. 304, No. 1, pp. 56-62, Sep. 9, 2002.
Kim, S. et al., “Transient Receptor Potential Vanilloid Subtype 1 Mediates Cell Death of Mesencephalic Dopaminergic Neurons In Vivo and In Vitro”,The Journal of Neuroscience, vol. 25(3), pp. 662-671, Jan. 19, 2005.
Kamei, J. et al., “Role of vanilloid VR1 receptor in thermal allodynia and hyperalgesia in diabetic mice”,European Journal of Pharmacology, vol. 422, pp. 83-86, May 15, 2001.
Chan, C. et al., “Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency”,Lancet, vol. 361, pp. 385-391, Feb. 1, 2003.
Yiangou, Y. et al., “Vanilloid receptor 1 immunoreactivity in inflamed human bowel”,Lancet, vol. 357, pp. 1338-1339, Apr. 28, 2001.
Holzer, P., “TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia”,European Journal of Pharmacology, vol. 500, pp. 231-241, Aug. 24, 2004.
Hwang, S. et al., “Hot channels in airways: pharmacology of the vanilloid receptor”,Current Opinion in Pharmacology, vol. 2, pp. 235-242, 2002.
Geppetti, P. et al., “The transient receptor potential vanilloid 1: Role in airway inflammation and disease”,European Journal of Pharmacology, vol. 533, pp. 207-214, Feb. 7, 2006.
Birder, L. et al., “Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1”,Nature Neuroscience, vol. 5, No. 9, pp. 856-860, Sep. 2002.
Birder, L. et al., “Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells”,PNAS, vol. 98, No. 23, pp. 13396-13401, Nov. 6, 2001.
Southall, M. et al., “Activation of Epidermal Vanilloid Receptor-1 Induces Release of Proinflammatory Mediators in Human Keratinocytes”,Journal of Pharmacology and Experimental Therapeutics, vol. 304, No. 1, 217-222, Sep. 13, 2002.
Tominaga, M. et al., “The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli”,Neuron, vol. 21, pp. 531-543, Sep. 1998.
Balaban, C. et al., “Type 1 vanilloid receptor expression by mammalian inner ear ganglion cells”,Hearing Research, vol. 175, pp. 165-170, Oct. 21, 2002.
Scotland, R. et al., “Vanilloid Receptor TRPV1, Sensory C-Fibers, and Vascular Autoregulation: A Novel Mechanism Involved in Myogenic Constriction”,Circulation Research, vol. 95, pp. 1027-1034, Oct. 12, 2004.
Bae Joon Ho
Choi Jin Kyu
Jeong Yeon Su
Kim Hee-Doo
Kim Jin Kwan
Amorepacific Corporation
Kumar Shailendra
Rothwell Figg Ernst & Manbeck P.C.
LandOfFree
Compounds, isomer thereof, or pharmaceutically acceptable... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, isomer thereof, or pharmaceutically acceptable..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds, isomer thereof, or pharmaceutically acceptable... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2710512